Internal Medicine Alert - September 30, 2006

Target Audience:

This activity is intended for the internist and family practitioner.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editor
Stephen Brunton, MD
Clinical Professor
University of California, Irvine

Peer Reviewer
Gerald Roberts, MD
Assistant Clinical Professor of Medicine
Albert Einstein College of Medicine
New York, NY

Associate Editors
Joseph E. Scherger, MD, MPH
Professor
University of California, San Diego

Allan J. Wilke, MD
Residency Program Director
Associate Professor of Family Medicine
University of Alabama
Birmingham School of Medicine
Huntsville Regional Medical Campus
Huntsville

James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Manager
Kaiser Permanente
Oakland, CA

William T. Elliott, MD, FACP
Chair
Formulary Committee
Northern California Kaiser Permanente;
Asst. Clinical Professor of Medicine
University of California
San Francisco

Malcolm Robinson, MD, FACP, FACG
Emeritus Clinical Professor of Medicine
University of Oklahoma College of Medicine
Oklahoma City

Louis Kuritzky, MD
Clinical Assistant Professor
University of Florida
Gainesville

Authors
Matthew E. Fink, MD
Vice Chairman
Professor of Clinical Neurology
Weill Cornell Medical College;
Chief
Division of Stroke and Critical Care Neurology
NewYork--Presbyterian Hospital

Carol A. Kemper, MD, FACP
Clinical Associate Professor of Medicine
Stanford University
Division of Infectious Diseases
Santa Clara Valley Medical Center

Subjects:

  • Finally an Optimal Strategy for Diagnosing Deep Vein Thrombosis
  • Esomeprazole 40 mg Once a Day in Patients with Functional Dyspepsia
  • Oral Anticoagulation for Stroke Prevention in AF
  • Does HCV Really Go Away?
  • Antibiotics for Acute Purulent Rhinitis? 'S not a Good Idea
  • Efavirenz/Emtricitabine/Tenofovir Tablets (Atripla)
  • Clinical Briefs By Louis Kuritzky, MD

Objectives:

  • Describe new findings in differential diagnosis and treatment of various diseases
  • Describe controversies, advantages, and disadvantages of those advances
  • Describe cost-effective treatment regimens

Financial Disclosure:

Internal Medicine Alert's Editor, Stephen Brunton, MD, is a consultant for Sanofi-Aventis, Ortho-McNeil, McNeil, Abbott, Novo Nordisk, Eli Lilly, Endo, EXACT Sciences, and Astra-Zeneca, and serves on the speaker's bureau of McNeil, Sanofi-Aventis, and Ortho-McNeil. Peer reviewer Gerald Roberts, MD, and associate editors Joseph E. Scherger, MD, MPH, Allan J. Wilke, MD, James Chan, PharmD, PhD, and William T. Elliott, MD, FACP, and authors Matthew E. Fink, MD, and Carol A. Kemper, MD, FACP report no financial relationships to this field of study. Associate editor Malcolm Robinson, MD, FACP, FACG serves as a consultant for TAP, Pfizer, Janssen, Eisai, J&J-Merck, and Procter & Gamble, is on the speaker's bureau of Janssen, Eli Lilly, Solvay, TAP, and Aventis, and does research for Forest Labs, Wyeth-Ayerst, AstraZeneca, and Centocor. Associate editor Louis Kuritzky, MD is a consultant for GlaxoSmithKline and is on the speaker's bureau of GlaxoSmithKline, 3M, Wyeth-Ayerst, Pfizer, Novartis, Bristol-Myers Squibb, AstraZeneca, Jones Pharma, and Boehringer Ingelheim.

Copyright 2006 AHC Media. All rights reserved.